News

ALX Oncology reports ‘encouraging’ final results from Phase 1 evorpacept trial
ALX Oncology (ALXO) announced “encouraging” data from an ongoing Phase 1/2 investigator-sponsored trial of the company’s lead clinical ...
Seeking Alpha3d
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin ...
Details of the poster to be presented at AACR 2025 are as follows: A copy of the AACR 2025 IST presentation will be available in the “Publications” section of the ALX Oncology website ...
Business Insider3d
ALX Oncology reports ASPEN-03, ASPEN-04 trials did not meet primary endpoints
ALX Oncology (ALXO) announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company’s investigational CD47-blocker evorpacept, when added to Merck’s (MRK) anti-PD-1 ...
Yahoo Finance21d
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...